175 related articles for article (PubMed ID: 30057378)
21. Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer.
Wei Q; Zhang J; Li Z; Wei L; Ren L
Pancreas; 2020 Oct; 49(9):1213-1219. PubMed ID: 32898008
[TBL] [Abstract][Full Text] [Related]
22. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczynska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2004 Mar; 42(3):256-60. PubMed ID: 15080556
[TBL] [Abstract][Full Text] [Related]
23. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
24. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
25. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
26. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B
Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847
[TBL] [Abstract][Full Text] [Related]
27. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.
Pawluczuk E; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680333
[TBL] [Abstract][Full Text] [Related]
28. ERCP combined with tumor markers in differential diagnosis of pancreatic cancer and pseudotumor-like pancreatitis.
Luo B; Peng F; Hong M; Su S; Fang C; Yang X; Xia G; Li B
J BUON; 2019; 24(4):1568-1573. PubMed ID: 31646810
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
30. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
31. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
32. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
33. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
[TBL] [Abstract][Full Text] [Related]
34. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.
Dressen K; Hermann N; Manekeller S; Walgenbach-Bruenagel G; Schildberg FA; Hettwer K; Uhlig S; Kalff JC; Hartmann G; Holdenrieder S
Anticancer Res; 2017 May; 37(5):2477-2486. PubMed ID: 28476816
[TBL] [Abstract][Full Text] [Related]
37. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
38. CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer.
Franz JM; Portela P; Salim PH; Berger M; Fernando Jobim L; Roesler R; Jobim M; Schwartsmann G
Cytokine; 2017 Sep; 97():193-200. PubMed ID: 28668699
[TBL] [Abstract][Full Text] [Related]
39. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
[TBL] [Abstract][Full Text] [Related]
40. Serum CXCL8 and CXCR2 as diagnostic biomarkers for noninvasive screening of cervical cancer.
Zhang N; Pang C; Li Z; Xu F; Zhao L
Medicine (Baltimore); 2023 Aug; 102(34):e34977. PubMed ID: 37653753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
